JOURNAL OF VIRAL HEPATITIS

Roadmap to functional cure of chronic hepatitis B: An expert consensus

Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients

Persistence of HBsAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults

Direct‐acting antivirals for HCV treatment in older patients: A systematic review and meta‐analysis

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Add‐on peginterferon alfa‐2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen‐negative chronic hepatitis B genotype D

Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort

Modelling the potential prevention benefits of a treat‐all hepatitis C treatment strategy at global, regional and country levels: A modelling study

Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B

Management of Hepatitis C Infection in children in the era of Direct‐acting Antiviral Agents

Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB‐4 for staging liver fibrosis in chronic viral hepatitis

Loss to follow‐up: A significant barrier in the treatment cascade with direct‐acting therapies

Expression of programmed cell death protein 1 and T‐cell immunoglobulin‐ and mucin‐domain‐containing molecule‐3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus

Maternal HBsAg carriers and adverse pregnancy outcomes: A hospital‐based prospective cohort analysis

COPII cargo claudin‐12 promotes hepatitis C virus entry

Soluble programmed death‐1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B

Evolution of renal function under direct‐acting antivirals treatment for chronic hepatitis C: A real‐world experience

High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Improving hepatitis C direct‐acting antiviral access and uptake: A role for patient‐reported outcomes and lived experience

Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B

Genetic diversity of hepatitis D virus genotype‐1 in Europe allows classification into subtypes

Advanced liver disease in Russian children and adolescents with chronic hepatitis C

A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study

Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion

HIV co‐infection is associated with increased transmission risk in patients with chronic hepatitis C virus

Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis

The dynamic effect of direct‐acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C

Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection

Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real‐world chronic hepatitis C patients cohort

Real‐world impact following initiation of interferon‐free hepatitis C regimens on liver‐related outcomes and all‐cause mortality among patients with compensated cirrhosis

SLC10A1 S267F variant influences susceptibility to HBV infection and reduces cholesterol level by impairing bile acid uptake

High rates of unprotected anal sex and use of generic direct‐acting antivirals in a cohort of MSM with acute HCV infection

Attitudes, practices and perceived barriers to hepatitis C screening among medical residents at a large urban academic medical center

Efficacy of antepartum administration of hepatitis B immunoglobulin in preventing mother‐to‐child transmission of hepatitis B virus

Nurse case management to improve the hepatitis C care continuum in HIV co‐infection: Results of a randomized controlled trial

The testing of people with any risk factor for hepatitis C in community pharmacies is cost‐effective

Ovarian HBV replication following ovulation induction in female hepatitis B carriers undergoing IVF treatment: A prospective observational study

Effectiveness of single‐dose administration of inactivated hepatitis A virus vaccination in the Republic of Korea armed forces, 2013‐2016

p38 mitogen‐activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg‐negative chronic hepatitis B

Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016

Last crusade against HCV: Direct‐acting antiviral treatment for marginalized populations

Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection

Hepatitis B in sub‐Saharan Africa—How many patients need therapy?

Cytomegalovirus and hepatitis after bone marrow transplantation

Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high‐risk groups

Unreported alcohol use was common but did not impact hepatitis C cure in HIV‐infected persons who use drugs